| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.05 | 0.3 |
| mRNA | serdemetan | FIMM | pan-cancer | AAC | -0.16 | 0.3 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.03 | 0.3 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.031 | 0.3 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.032 | 0.3 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.3 |